期刊论文详细信息
Nutrition Journal
Modulation of human postprandial lipemia by changing ratios of polyunsaturated to saturated (P/S) fatty acid content of blended dietary fats: a cross-over design with repeated measures
Kalyana Sundram2  Tilakavati Karupaiah1 
[1] National University of Malaysia, Bangi, Malaysia;Faculty of Health Sciences, National University of Malaysia, Kuala Lumpur, Malaysia
关键词: Lipoproteins;    P/S ratio;    Dietary fats;    Postprandial lipemia;   
Others  :  805834
DOI  :  10.1186/1475-2891-12-122
 received in 2013-01-17, accepted in 2013-08-12,  发布年份 2013
PDF
【 摘 要 】

Background

Postprandial lipemia (PL) contributes to coronary artery disease. The fatty acid composition of dietary fats is potentially a modifiable factor in modulating PL response.

Methods

This human postprandial study evaluated 3 edible fat blends with differing polyunsaturated to saturated fatty acids (P/S) ratios (POL = 0.27, AHA = 1.00, PCAN = 1.32). A cross-over design included mildly hypercholestrolemic subjects (9 men and 6 women) preconditioned on test diets fats at 31% energy for 7 days prior to the postprandial challenge on the 8th day with 50 g test fat. Plasma lipids and lipoproteins were monitored at 0, 1.5, 3.5, 5.5 and 7 hr.

Results

Plasma triacylglycerol (TAG) concentrations in response to POL, AHA or PCAN meals were not significant for time x test meal interactions (P > 0.05) despite an observed trend (POL > AHA > PCAN). TAG area-under-the-curve (AUC) increased by 22.58% after POL and 7.63% after PCAN compared to AHA treatments (P > 0.05). Plasma total cholesterol (TC) response was not significant between meals (P > 0.05). Varying P/S ratios of test meals significantly altered prandial high density lipoprotein-cholesterol (HDL-C) concentrations (P < 0.001) which increased with decreasing P/S ratio (POL > AHA > PCAN). Paired comparisons was significant between POL vs PCAN (P = 0.009) but not with AHA or between AHA vs PCAN (P > 0.05). A significantly higher HDL-C AUC for POL vs AHA (P = 0.015) and PCAN (P = 0.001) was observed. HDL-C AUC increased for POL by 25.38% and 16.0% compared to PCAN and AHA respectively. Plasma low density lipoprotein-cholesterol (LDL-C) concentrations was significant (P = 0.005) between meals and significantly lowest after POL meal compared to PCAN (P = 0.004) and AHA (P > 0.05) but not between AHA vs PCAN (P > 0.05). AUC for LDL-C was not significant between diets (P > 0.05). Palmitic (C16:0), oleic (C18:1), linoleic (C18:2) and linolenic (C18:3) acids in TAGs and cholesteryl esters were significantly modulated by meal source (P < 0.05).

Conclusions

P/S ratio of dietary fats significantly affected prandial HDL-C levels without affecting lipemia.

【 授权许可】

   
2013 Karupaiah and Sundram; licensee BioMed Central Ltd.

【 预 览 】
附件列表
Files Size Format View
20140708083611241.pdf 399KB PDF download
Figure 4. 63KB Image download
Figure 4. 63KB Image download
Figure 4. 63KB Image download
Figure 4. 63KB Image download
Figure 3. 65KB Image download
Figure 3. 65KB Image download
Figure 3. 65KB Image download
Figure 3. 65KB Image download
Figure 2. 59KB Image download
Figure 2. 59KB Image download
Figure 2. 59KB Image download
Figure 2. 59KB Image download
Figure 1. 50KB Image download
Figure 1. 50KB Image download
Figure 1. 50KB Image download
Figure 1. 50KB Image download
【 图 表 】

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 2.

Figure 2.

Figure 2.

Figure 2.

Figure 3.

Figure 3.

Figure 3.

Figure 3.

Figure 4.

Figure 4.

Figure 4.

Figure 4.

【 参考文献 】
  • [1]Zilversmit DB: Atherogenesis: a postprandial phenomenon. Circulation 1979, 60:473-485.
  • [2]Patsch JR: Triglyceride rich lipoproteins and atherosclerosis. Artherosclerosis 1994, 110:S23-S26.
  • [3]Karpe F: Postprandial lipoprotein metabolism and atherosclerosis. J Int Med 1999, 246:341-355.
  • [4]Roche HM, Gibney MJ: Postprandial coagulation factor VII activity: the effects of monounsaturated fatty acids. Brit J Nutr 1997, 77:537-549.
  • [5]Nestel PJ, Shige H, Pomeroy S, Cehun M, Chin-Dusting J: Post-prandial remnant lipids impair arterial complicance. J Am Coll Cardiol 2001, 37:1929-1935.
  • [6]Goldberg IJ, Kako Y, Lutz EP: Responses to eating: lipoproteins, lipolytic products and atherosclerosis. Curr Opin Lipidol 2000, 11:235-241.
  • [7]Expert Panel: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
  • [8]Assmann G, Schulte H, von Eckardstein A, Huang Y: High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996, 124(Suppl):S11-S20.
  • [9]Despres JP, Lemieux I, Dagenais GR, Cantin B, Lamarche B: HDL-cholesterol as a marker of coronary heart disease risk: the Quebec cardiovascular study. Atherosclerosis 2000, 153:263-272.
  • [10]Van Horn L, Mccoin M, Kris-Etherton PM, Burke F, Carson AS, Champagne CM, Karmally W, Sikand G: The evidence for dietary prevention and treatment of cardiovascular disease. J Am Diet Assoc 2008, 108:287-331.
  • [11]Sanders TAB, Berry SEE, Miller GJ: Influence of triacylglycerol structure on the postprandial response of factor VII to stearic acid-rich fats. Am J Clin Nutr 2003, 77:777-782.
  • [12]Lichtenstein AH, Matthan NR, Jalbert SM, Resteghini NA, Schaefer EJ, Ausman LM: Novel soybean oils with different fatty acid profiles alter cardiovascular disease risk factors in moderately hyperlipidemic subjects. Am J Clin Nutr 2006, 84:497-504.
  • [13]Crupkin M, Zambelli A: Detrimental impact of trans fats on human health: Stearic acid-rich fats as possible substitutes. Comp Rev in Food Sci Food Safety 2008, 7:271-279.
  • [14]Hunter JE, Zhang J, Kris-Etherton PM: Cardiovascular risk of dietary stearic acid compared with trans, other saturated and undsaturated fatty acids: a systematic review. Am J Clin Nutr 2010, 91:46-63.
  • [15]Hayes KC for the Expert Panel: Consensus statement- Fatty acid expert roundtable: Key statements about fatty acids. J Am Coll Nutr 2010, 29:285S-288S.
  • [16]Astrup A, Dyerberg J, Elwood P, Hermansen PK, Hu FB, Jakobsen MU, Kok FJ, Krauss RM, Lecerf JM, LeGrand P, Nestel P, Rise´rus U, Sanders T, Sinclair A, Stender S, Tholstrup T, Willett WC: The role of reducing intakes of saturated fat in the prevention of cardiovascular disease: where does the evidence stand in 2010? Am J Clin Nutr 2011, 93:684-688.
  • [17]Lairon D, Lopez-Miranda J, Williams C: Methodology for studying postprandial lipid metabolism. Eur J Clin Nutr 2007, 61:1145-1161.
  • [18]Sakr SW, Haourigui M, Paul JL, Soni T, Vachter D, Girard-Globa A: Fatty acid composition of an oral fat load affects chylomicron size in human subjects. Brit J Nutr 1997, 77:19-31.
  • [19]Zampelas A, Peel AS, Gould BJ, Wright J, Williams CM: Polyunsaturated fatty acids of the n-6 and n-3 series: effects on postprandial lipid and apolipoprotein levels in healthy men. EurJ Clin Nutr 1994, 48:842-848.
  • [20]Weintraub MS, Zechner R, Brown A, Eisenberg S, Breslow JL: Dietary polyunsaturated fats of the w-6 and w-3 series reduce postprandial lipoprotein levels: chronic and acute effects of fat saturation on postprandial lipoprotein metabolism. J Clin Invest 1988, 82:1884-1893.
  • [21]Zampelas A, Williams CM, Morgan LM, Wright J, Quinlan PT: The effect of triacylglycerol fatty acid positional distribution on postprandial plasma metabolite and hormone responses in normal adult men. Br J Nutr 1994, 71:401-410.
  • [22]Karupaiah T, Tan CH, Chinna K, Sundram K: The chain length of dietary saturated fatty acids affects human postprandial lipemia. J Am Coll Nutr 2011, 30:511-521.
  • [23]Sundram K, Karupaiah T, Hayes KC: Stearic acid-rich interesterified fat and trans-rich fat raise the LDL/HDL ratio and plasma glucose relative to palm olein in humans. Nutrition & Metabolism 2007, 4:3. BioMed Central Full Text
  • [24]Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC: Enzymatic determination of total serum cholesterol. Clin Chem 1974, 20:470-475.
  • [25]Nägele U, Hagele EO, Sauer G, Wiedemann E, Lehmann P, Wahlefeld AW, Gruber W: Reagent for the enzymatic determination of serum total triglycerides with improved lipolytic efficiency. J Clin Chem Clin Biochem 1984, 22:165-174.
  • [26]Warnick GH, Benderson J, Albers JJ: Dextran sulfate- Mg2+ precipitation procedure for quantitation of high-density lipoprotein cholesterol. Clin Chem 1982, 28:1379-1388.
  • [27]Finley PR, Schifman RB, Williams RJ, Lichti DA: Cholesterol in high-density lipoprotein; use of Mg2+/dextran sulfate in its enzymatic measurement. Clin Chem 1978, 24:931-933.
  • [28]Friedewald WT, Levy RI, Frederickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
  • [29]Matthews JNS, Altman DG, Campbell MJ, Royston P: Analysis of serial measurements in medical research. BMJ 1990, 300:230-235.
  • [30]Lopes SM, Trimbo SL, Mascioli EA, Blackburn GL: Human plasma fatty acid variations and how they are related to dietary intake. Am J Clin Nutr 1991, 53:628-637.
  • [31]Obarzanek E, Kimm SY, Barton BA, Van Horn L, Kwiterovich PO Jr, Simons-Morton DG, Hunsberger SA, Lasser NL, Robson AM, Franklin FA Jr, Lauer RM, Stevens VJ, Friedman LA, Dorgan JF, Greenlick MR: Long-term safety and efficacy of a cholesterol-lowering diet in children with elevated low-density lipoprotein cholesterol: Seven-year results of the Dietary Intervention Study in Children (DISC). Pediatrics 2001, 107:256-264.
  • [32]Ginsberg HN, Kris-Etherton P, Dennis B, Elmer PJ, Ershow A, Lefevre M, Pearson T, Roheim P, Ramakrishnan R, Reed R, Stewart K, Stewart P, Phillips K, Anderson N, for the Delta Research Group: Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects- The Delta Study, Protocol 1. Arterioscler Thromb Vasc Biol 1998, 18:441-449.
  • [33]Howard BV, Van Horn L, Hsia J, Manson JE, Stefanick ML, Wassertheil-Smoller S, Kuller LH, LaCroix AZ, Langer RD, Lasser NL, Lewis CE, Limacher MC, Margolis KL, Mysiw WJ, Ockene JK, Parker LM, Perri MG, Phillips L, Prentice RL, Robbins J, Rossouw JE, Sarto GE, Schatz IJ, Snetselaar LG, Stevens VJ, Tinker LF, Trevisan M, Vitolins MZ, Anderson GL, Assaf AR, Bassford T, Beresford SA, Black HR, Brunner RL, Brzyski RG, Caan B, Chlebowski RT, Gass M, Granek I, Greenland P, Hays J, Heber D, Heiss G, Hendrix SL, Hubbell FA, Johnson KC, Kotchen JM: Low-fat dietary pattern and risk of cardiovascular disease: The Women’s Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 2006, 295:655-666.
  • [34]Lichtenstein AH, Ausman LM, Jalbert SM, Vilella-Bach M, Jauhiainen M, McGladdery S, Erkkila AT, Ehnholm C, Frohlich J, Schaefer EJ: Efficacy of a Therapeutic Lifestyle Change/Step 2 diet in moderately hypercholesterolemic middle-aged and elderly female and male subjects. J Lipid Res 2002, 43:264-273.
  • [35]Appel LJ, Sacks FM, Carey VJ, Obarzanek E, Swain JF, Miller ER 3rd, Conlin PR, Erlinger TP, Rosner BA, Laranjo NM, Charleston J, McCarron P, Bishop LM: Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: Results of the OmniHeart randomized trial. JAMA 2005, 294:2455-2464.
  • [36]Retzlaff BM, Walden CW, Dowdy AA, McCann BS, Anderson KA, Knopp RH: Changes in plasma triacylglycerol concentrations among free-living hyperlipidemic men adopting different carbohydrate intakes over 2 y: the Dietary Alternatives Study. Am J Clin Nutr 1995, 62:988-995.
  • [37]Parks EJ, Hellerstein MK: Carbohydrate-induced hypertriacylglycerolemia: historical perspective and review of biological mechanisms. Am J Clin Nutr 2000, 71:412-433.
  • [38]Barter PJ, Rye KA: Cholesteryl ester transfer protein, high density lipoprotein and arterial disease. Curr Opin Lipid 2001, 12:377-382.
  • [39]Cohn JS, McNamara JR, Krasinski SD, Russell RM, Schaefer EJ: Role of triglyceride-rich lipoproteins from the liver and intestine in the etiology of postprandial peaks in plasma triglyceride concentration. Metabolism 1989, 38:484-490.
  • [40]Jensen J, Bysted A, Dawids S, Hermansen K, Holmer G: The effect of palm oil, lard, and puff-pastry margarine on postprandial lipid and hormone responses in normal-weight and obese young women. Brit J Nutr 1999, 82:469-479.
  • [41]Cohen JC, Noakes TD, Benade AJS: Serum triglyceride responses to fatty meals: effects of meal fat content. Am J Clin Nutr 1988, 47:825-827.
  • [42]Pedersen A, Marckmann P, Sandström B: Postprandial lipoprotein, glucose and insulin responses after two consecutive meals containing rapeseed oil, sunflower oil or palm oil with or without glucose at the first meal. Brit J Nutr 1999, 82:97-104.
  • [43]Demacker PNM, Reijnen IGM, Katan MB, Stuyt PMJ, Stalenhoef AFH: Increased removal of remnants of triglyceride-rich lipoproteins on a diet rich in polyunsaturated fatty acids. Eur J Clin Invest 1991, 21:197-203.
  • [44]Sultan F, Langrange D, Jansen H, Griglio S: Inhibition of hepatic lipase activity impairs chylomicron remnant removal in rats. Biochim Biophys Acta 1990, 1042:150-152.
  • [45]Rahman MH, Avella MA, Botham KM: The fatty acid composition of chylomicrons influences the rate of their lipolysis in vivo. Nutr Metab Cardiovasc Dis 2000, 10:121-1225.
  • [46]Sundram K, Hayes KC, Siru OH: Dietary palmitic acid results in a lower serum cholesterol than a lauric-myristic acid combination in normolipemic humans. Am J Clin Nutr 1994, 59:841-846.
  • [47]Sundram K: Modulation of human lipids and lipoproteins by dietary palm oil and palm olein: a review. Asia Pac J Clin Nutr 1997, 6:12-16.
  • [48]Sundram K, Hayes KC, Siru OH: Both dietary 18:2 and 16:0 may be required to improve the serum LDL/HDL cholesterol ratio in normocholesterolemic men. J Nutr Biochem 1995, 6:179-187.
  • [49]Bhatt KN, Wells BJ, Sperling LS, Baer JT: High-density lipoprotein therapy: is there hope? Curr Treatment Options Cardiovasc Med 2010, 12:315-328.
  • [50]Singh V, Sharma R, Kumar A, Deedwania P: Low high-density lipoprotein cholesterol: Current status and future strategies for management. Vas Health Risk Manag 2011, 6:979-996.
  • [51]Hausenloy DJ, Yellon DM: Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Postgrad Med J 2008, 84:590-598.
  • [52]National Heart, Lung and blood Institute: NIH stops clinical trial on combination cholesterol treatment. NIH News [press release May 26 2011]. http://www.nih.gov/news/health/may2011/nhlbi-26.htm webcite. Accessed July 31, 2011
  • [53]Marcason W: What role does HDL cholesterol have in CVD and what is the most effective way to increase it? J Am Diet Assoc 2011, 111:1266.
  文献评价指标  
  下载次数:82次 浏览次数:21次